Related Experiment Video
Updated: Jun 16, 2026
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term
Tijl Vermassen1,2,3, Charlotte Van Parijs1, Stijn De Keukeleire1
1Department Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
Background:
Survival of patients with brain metastases (BMs) is poor. It has become clear that targeted therapy has an effect on BMs and patient' prognosis. The question remains which patients benefit from additional systemic therapy. This assumption was evaluated in a large single-center cohort.
Methods:
Patients consecutively planned to undergo local radiotherapy for their BMs in 2006-2017 were selected (n = 200). Prognosis, using CERENAL, disease-specific graded prognostic assessment (DS-GPA), and Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA), was evaluated.
Results:
Ninety-three (46.5%) patients received at least one additional line of systemic therapy subsequent to the diagnosis of their BMs. The median overall survival (OS) was 6.3 months. Having received subsequent systemic therapy resulted in a more favorable OS (10.4 versus 3.9 months). Interestingly, using dichotomized scores, CERENAL showed prognostic properties in all patients for disease-specific survival on multivariate analysis, whereas RTOG RPA and DS-GPA were not withheld in the model. Lastly, only having a favorable DS-GPA resulted in prolonged progression-free survival for first systemic therapy following BM diagnosis.
Conclusions:
Receiving subsequent systemic therapy has a profound influence on outcome in patients with BMs, indicating the effect of systemic therapy on BMs. Use of the CERENAL brain prognostic score shows potential for further prognostication of patients with more favorable outcomes.
